Related Experiment Video
Updated: Aug 7, 2026

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery
Published on: November 5, 2019
Annual report of the Australian Meningococcal Surveillance Programme, 2005
Abstract:
In 2005 there were 345 laboratory-confirmed cases of invasive meningococcal disease (IMD) analysed by the National Neisseria Network, a nationwide network of reference laboratories. The phenotypes (serogroup, serotype and serosubtype) and antibiotic susceptibility of 214 isolates of Neisseria meningitidis from invasive cases of meningococcal disease were determined and an additional 131 cases were confirmed by non-culture-based methods. Nationally, 251 (73%) confirmed cases were infected with serogroup B and 50 (14.5%) with serogroup C meningococci. The total number of confirmed cases was 16 fewer than the 361 cases identified in 2004. The number of cases decreased in Queensland, Tasmania, New South Wales and the Australian Capital Territory and increased slightly in Victoria, South Australia, Western Australia and the Northern Territory. The age distribution of IMD showed a typical primary peak in those aged four years or less with a lower secondary peak in adolescents and young adults. Serogroup B cases were 90 per cent of all cases in those aged four years or less and 75 per cent in those aged 15-24 years. The proportion of all invasive disease represented by serogroup C disease was highest in the 20-24 years and older age groups. The common phenotypes circulating in Australia were B:15:P1.7 and C:2a:P1.5. However significant jurisdictional differences in the serogroup and phenotypic distribution of meningococci were again evident and considerable heterogeneity of subtypes was noted. No evidence of meningococcal capsular 'switching' or genetic recombination was detected. About two thirds of all isolates showed decreased susceptibility to the penicillin group of antibiotics (MIC 0.06-0.5 mg/L). A single isolate was penicillin resistant at 1 mg/L and another was rifampicin resistant.
Insights
Invasive meningococcal disease (IMD) cases decreased in 2005, with serogroup B predominating, especially in younger age groups. Antibiotic susceptibility testing revealed reduced penicillin susceptibility in most isolates.
Area of Science:
- Microbiology
- Epidemiology
- Public Health
Background:
- Invasive meningococcal disease (IMD) remains a significant public health concern.
- Surveillance of Neisseria meningitidis is crucial for understanding disease trends and guiding prevention strategies.
Purpose of the Study:
- To analyze the epidemiology and antimicrobial susceptibility of invasive meningococcal disease (IMD) cases in Australia during 2005.
- To identify circulating serogroups, serotypes, and serosubtypes of Neisseria meningitidis.
Main Methods:
- Laboratory confirmation of 345 IMD cases through the National Neisseria Network.
- Phenotypic characterization (serogroup, serotype, serosubtype) of 214 Neisseria meningitidis isolates.
- Antibiotic susceptibility testing of isolates.
Main Results:
- A total of 345 confirmed IMD cases were reported, a decrease from 2004.
- Serogroup B (73%) and serogroup C (14.5%) were the predominant serogroups.
- Typical age distribution with peaks in <4 years and adolescents/young adults observed.
- Serogroup B was most common in <4 years (90%) and 15-24 years (75%).
- Serogroup C disease was highest in older age groups (20-24 years and above).
- Common phenotypes were B:15:P1.7 and C:2a:P1.5, with jurisdictional variations.
- Two-thirds of isolates showed decreased penicillin susceptibility; one isolate was penicillin-resistant.
Conclusions:
- Invasive meningococcal disease incidence decreased in Australia in 2005.
- Serogroup B remains the dominant cause of IMD, particularly in young children and adolescents.
- Reduced susceptibility to penicillin is a growing concern, necessitating ongoing surveillance and antimicrobial stewardship.
Related Concept Videos
Bacterial Meningitis I: Introduction
Viral Meningitis
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Cryptococcal Meningitis

